3,000 Shares in SPDR S&P Biotech (XBI) Acquired by Telemus Capital LLC

Telemus Capital LLC acquired a new position in shares of SPDR S&P Biotech (NYSEARCA:XBI) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,000 shares of the exchange traded fund’s stock, valued at approximately $232,000.

Other large investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. raised its position in shares of SPDR S&P Biotech by 61.7% in the second quarter. Russell Investments Group Ltd. now owns 49,141 shares of the exchange traded fund’s stock valued at $3,792,000 after buying an additional 18,746 shares in the last quarter. David R. Rahn & Associates Inc. raised its position in shares of SPDR S&P Biotech by 51.7% in the second quarter. David R. Rahn & Associates Inc. now owns 38,631 shares of the exchange traded fund’s stock valued at $2,982,000 after buying an additional 13,170 shares in the last quarter. Janney Montgomery Scott LLC raised its position in shares of SPDR S&P Biotech by 10.9% in the second quarter. Janney Montgomery Scott LLC now owns 98,057 shares of the exchange traded fund’s stock valued at $7,568,000 after buying an additional 9,655 shares in the last quarter. Bray Capital Advisors raised its position in shares of SPDR S&P Biotech by 120.3% in the second quarter. Bray Capital Advisors now owns 15,610 shares of the exchange traded fund’s stock valued at $1,205,000 after buying an additional 8,525 shares in the last quarter. Finally, Papp L Roy & Associates raised its position in shares of SPDR S&P Biotech by 3.1% in the second quarter. Papp L Roy & Associates now owns 187,538 shares of the exchange traded fund’s stock valued at $14,474,000 after buying an additional 5,648 shares in the last quarter.

SPDR S&P Biotech (NYSEARCA XBI) traded down 0.11% on Friday, hitting $74.95. 4,771,566 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $78.04 and a 200-day moving average price of $72.03. SPDR S&P Biotech has a 52-week low of $53.15 and a 52-week high of $82.38.

ILLEGAL ACTIVITY WARNING: This report was originally reported by BNB Daily and is the property of of BNB Daily. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.baseball-news-blog.com/2017/08/19/telemus-capital-llc-buys-new-stake-in-spdr-sp-biotech-xbi-updated.html.

SPDR S&P Biotech Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply